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ABSTRACT
Objective To determine the effect of glucosamine,
chondroitin, or the two in combination on joint pain and
on radiological progression of disease in osteoarthritis of
the hip or knee.
DesignNetworkmeta-analysis. Direct comparisonswithin
trials were combined with indirect evidence from other
trials by using a Bayesian model that allowed the
synthesis of multiple time points.
Main outcome measure Pain intensity. Secondary
outcome was change in minimal width of joint space. The
minimal clinically important difference between
preparations and placebo was prespecified at −0.9 cm on
a 10 cm visual analogue scale.
Data sources Electronic databases and conference
proceedings from inception to June 2009, expert contact,
relevant websites.
Eligibility criteria for selecting studies Large scale
randomised controlled trials in more than 200 patients
with osteoarthritis of the knee or hip that compared
glucosamine, chondroitin, or their combination with
placebo or head to head.
Results 10 trials in 3803 patients were included. On a 10
cm visual analogue scale the overall difference in pain
intensity compared with placebo was −0.4 cm (95%
credible interval −0.7 to−0.1 cm) for glucosamine, −0.3 cm
(−0.7 to 0.0 cm) for chondroitin, and −0.5 cm (−0.9 to 0.0
cm) for the combination. For none of the estimates did the
95% credible intervals cross the boundary of the minimal
clinically important difference. Industry independent trials
showed smaller effects than commercially funded trials
(P=0.02 for interaction). The differences in changes in
minimal width of joint space were all minute, with 95%
credible intervals overlapping zero.
Conclusions Compared with placebo, glucosamine,
chondroitin, and their combination do not reduce joint
pain or have an impact on narrowing of joint space. Health
authorities and health insurers should not cover the costs
of these preparations, and new prescriptions to patients
who have not received treatment should be discouraged.
INTRODUCTION
Osteoarthritis of the hip or knee is a chronic condition
mostly treated with analgesics and non-steroidal anti-
inflammatory drugs, but these drugs can cause serious
gastrointestinal and cardiovascular adverse events,
especially with long term use.1 2 Disease modifying
agents that not only reduce joint pain but also slow
the progression of the condition would be desirable.
Throughout the world for the past 10 years, the carti-
lage constituents chondroitin and glucosamine have
been increasingly recommended in guidelines, pre-
scribed by general practitioners and rheumatologists,
and usedby patients as over the countermedications to
modify the clinical and radiological course of the
condition.3 Global sales of glucosamine supplements
reached almost $2bn (£1.3bn, €0.8bn) in 2008, which
represents an increase of about 60% compared with
2003, with a forecasted continued growth through
2013 reaching $2.3bn.4 The oral administration of car-
tilage constituents in patients with osteoarthritis is
thought to make up for the apparent cartilage loss in
affected joints. Chondroitin is a highly hydrophilic, gel
forming polysaccharide macromolecule. Its hydrocol-
loid properties convey much of the compressive resis-
tance of cartilage. Glucosamine is an amino sugar that
is a building block for the glycosaminoglycans that are
part of the structure of cartilage. Ingested chondroitin
and glucosamine are both partially absorbed in the
intestine, and it has been suggested that some of the
ingested amount reaches the joints.5-7
Results from randomised trials about the effectiveness
of chondroitin andglucosamine are conflicting.8-11 Trials
that have reported large effects on joint pain were often
hampered by poor study quality and small sample
sizes,9-12 whereas large methodologically sound trials
often found only small or no effects.101113
Bayesian approaches towards network meta-ana-
lyses allow a unified, coherent analysis of data
recorded at multiple time points in randomised trials
that compare either of these preparations with placebo
or head to head.14-16 The approaches fully respect ran-
domisation, account for the correlation of multiple
observations within the same trial, and allow the esti-
mation of the relative effectiveness of the different pre-
parations and their combination. We performed a
systematic review with network meta-analysis includ-
ing data from large methodologically sound
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randomised trials at multiple follow-up times to deter-
mine the effect of these preparations on joint pain and
on radiological progression of disease.
METHODS
Literature search
We searched theCochraneControlled Trials Register,
Medline, Embase, and CINAHL (from inception to
June 2010) using a combination of keywords and text
words related to osteoarthritis; these were combined
with generic and trade names of the various prepara-
tions plus a validated filter for controlled clinical
trials.17 We also retrieved reports citing relevant arti-
cles via Science Citation Index (1981-2008). In addi-
tion, we manually searched conference proceedings
and text books, screened reference lists of all obtained
papers, and contacted content experts.
Study selection
We included randomised trials with an average of at
least 100 patients with knee or hip osteoarthritis per
arm.18 Trials compared chondroitin sulphate, glucosa-
mine sulphate, glucosamine hydrochloride, or the
combination of any two with placebo or head to
head. A sample size of 2×100 patients will yield more
than 80% power to detect a small to moderate effect
size of −0.40 at a two sided P=0.05, which corresponds
to a difference of 1 cm on a 10 cm visual analogue scale
between the experimental and control intervention.
Two of four reviewers (BT, EN, SR, ST) evaluated
reports independently for eligibility. They excluded
trial arms with sub-therapeutic doses (<800 mg/day
of chondroitin and <1500 mg/day of glucosamine, in
accordance with doses licensed in Europe). Disagree-
ments were resolved by consensus.
Outcome measures
The prespecified primary outcome was absolute pain
intensity reported in any of nine time windows orga-
nised in increments of threemonths (up to 3months, 6,
9, 12, 15, 18, 21 months, and 22 months or more). If
more than one time point was reported in a window,
we extracted data nearest to the longest follow-up time
included in that window; for the window covering
22 months or more, we extracted the follow-up closest
to 24 months. When an article provided data on more
than one pain scale, we referred to a previously
described hierarchy of pain related outcomes and
extracted the outcome that was highest on this list.9
Global pain took precedence over pain on walking
and pain subscores on the Western Ontario and
McMaster Universities (WOMAC) arthritis index. If
a trial report provided data on both—for example, glo-
bal pain scores and WOMAC pain subscores—we
recorded only data on global pain scores. Secondary
outcomes were changes in the minimum radiographic
joint space between baseline and the end of treatment,
the number of individuals withdrawn or who dropped
out because of an adverse event, and the number of
patients experiencing any adverse event.
Quality assessment
Two of the four reviewers independently assessed con-
cealment of allocation, blinding, and adequacy of
analyses.19 Concealment of allocation was considered
adequate if the investigators responsible for the selec-
tion of patients did not know before allocation which
treatment was next in line (central randomisation,
sealed, opaque, sequentially numbered assignment
envelopes, coded drug packs, etc). Any procedures
based on predictable generation of allocation
sequences, andpotentially transparent attempts to con-
ceal allocation, such as non-opaque envelopes, were
considered inadequate. We extracted the number of
patients initially randomised and the number of
patients analysed per group at each time point to dis-
tinguish between trials that had included all rando-
mised patients in the analysis (intention to treat
analysis) and trials that had not. Finally, we determined
whether experimental preparations had undergone
quality control—that is, if either a formally approved
preparation was used or pharmacological laboratory
analysis confirmed the content of the preparation. Dis-
agreements were resolved by consensus.
Data collection
Two of the four reviewers used a standardised form to
extract in duplicate data on publication status, trial
design, patients’ characteristics, treatment regimens,
outcome modalities, and funding. Results of pain,
joint space narrowing, and adverse events were extra-
cted by one reviewer (ST) and cross checked by
another (PJ). When necessary, means and measures
of dispersion were approximated from figures in the
reports.
Statistical analysis
We used an extension of multivariable Bayesian hier-
archical random effects models for mixed multiple
treatment comparisons with minimally informative
prior distributions.20 21 It fully preserves the compari-
son of randomised treatments within each trial while
combining all available comparisons between treat-
ments and accounts for multiple comparisons within
a trial when there are more than two treatment
arms.22 For the analysis of effect sizes of pain, the
model included random effects at the level of trials
and time points. It accounted for the correlation of out-
come data reported at different time points within a
trial and allowed the estimation of the variance of treat-
ment effects between trials (τ2). Effect sizes were calcu-
lated by dividing the differences in mean values
between treatment groups in a time window by the
median pooled standard deviation (SD) observed
across all time points in a trial.23 If SDs were not pro-
vided, we calculated them from standard errors or con-
fidence intervals as described elsewhere.10 24 An effect
size of −0.20 SD units suggests an overlap in the distri-
butions of reported pain scores in the experimental
group with pain scores in placebo group in 85% and
can be considered a small difference between experi-
mental and control group.9 23 An effect size of −0.50
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indicates an overlap in about 67% and can be consid-
ered a moderate difference, whereas −0.80 suggests an
overlap in 53% and is considered a large difference.9 23
To allow intuitive interpretation of pooled effects,
we back transformed effect sizes to differences on a
10 cm visual analogue scale on the basis of a median
pooled SD of 2.5 cm found in large scale osteoarthritis
trials that assessed pain on a 10 cm visual analogue
scale.12We prespecified aminimal clinically important
difference of 0.37 SDunits, corresponding to 0.9 cmon
a 10 cm visual analogue scale. This was based on the
median minimal clinically important difference found
in recent studies in patients with osteoarthritis.25-28 As
the analysis of changes of minimum radiographic joint
space did not include multiple time points, the model
used for this outcome included only a random effect at
the level of trials. To achieve comparability of themag-
nitude of effects on joint space and on pain and distin-
guish between small, moderate, and large treatment
effects, we expressed differences in the width of the
joint space as effect sizes, dividing the pooled estimates
in millimetres by the median pooled SD of 1.2 mm
found in included trials.
Whenever possible, we used results of intention to
treat analysis including all randomised patients.12
Pooled effect sizes were estimated from the median of
the posterior distribution. A negative effect size indi-
cates a benefit of the experimental intervention. Cor-
responding 95% credible intervals were estimated
from the 2.5th and 97.5th centiles of the posterior
distribution.15 In the presence of minimally informa-
tive priors, credible intervals can be interpreted in a
similar way to conventional confidence intervals. To
determine whether the variation of treatment effects
over time was over and above what would be expected
by chance, we calculated a P value for heterogeneity
across time points of follow-up.29 The P value was
derived from the proportion of observations of the pos-
terior distribution of the variance observed across time
pointswithin trials smaller thanor equal to the variance
within trials typically found in large osteoarthritis trials
(0.01 for an effect size scale, 0.0625 for a 10 cm visual
analogue scale).
To explore possible time trends,we included a linear
term for time as a covariate in the analyses. We then
included characteristics of the trials as covariates in the
network meta-analysis to estimate effects according to
concealment of allocation; intention to treat analysis;
high methodological quality defined as adequate con-
cealment of allocation, adequate blinding of patients,
and the presence of an intention to treat analysis;
source of funding (industry independent v other);
type of glucosamine used (sulphate v hydrochlorides);
quality control of preparations; and type of joint
affected (knee v hip). P values for interaction between
trial characteristics and treatment effect were derived
from the posterior distribution of covariates and can be
interpreted in the same way as a traditional P value for
interaction.30
Heterogeneity between trials was estimated from the
median variance between trials (τ²) observed in the
posterior distribution with the following prior distribu-
tions: a gamma distribution for heterogeneity between
trials (1/τ² gamma(0.001,0.001)I(0,2000)), and a uni-
form distribution for heterogeneity between time
points (τ unif(0,50)). In a sensitivity analysis we also
used a uniform prior for the heterogeneity between
trials. The consistency of the network was determined
by use of inconsistency factors: the estimated differ-
ence between the effect size from direct comparisons
within randomised trials and the effect size from indir-
ect comparisons between randomised trials with one
intervention in common.31 Estimates of variation and
consistency are based on back transformations to dif-
ferences on a 10 cm visual analogue scale. Goodness of
t was assessed with Q-Q plots.
Finally, we performed pairwise meta-analyses with
random effects at the level of trials and time points, as
well as a simpler networkmeta-analysis including only
one treatment effect per trial (absolute pain intensity at
the longest follow-up available). Convergence of Mar-
kov chains was deemed to be achieved if plots of the
Gelman-Rubin statistics indicated that widths of
pooled runs and individual runs stabilised around the
same value and their ratio around one.32 Accordingly,
all analyses are based on 150 000 iterations, of which
the first 50 000 were discarded as burn-in period. We
used Stata (Stata Statistical Software: release 10; Stata-
Corp LP 2005, College Station, TX) and WinBUGS
(version 1.4;MRCBiostatisticsUnit 2007,Cambridge,
UK) for all analyses.
RESULTS
Out of 58 potentially eligible reports, 12 reports
describing 10 trials met our inclusion criteria and
were included in the network meta-analysis.13 33-43 All
trials were published as full journal articles. For one
trial two publications were included1342; for another
trial43 additional data were provided in an electronic
rapid response.40
Study characteristics
The10 included trials had randomly allocated a total of
3803 patients to either of the experimental inter-
ventions or placebo. Figure 1 shows the network of
interventions. Five trials (1104 randomised patients)
compared glucosamine sulphate with placebo.33-35 39 41
In another placebo controlled trial (205 patients), the
investigators were forced to change from glucosamine
sulphate to glucosamine hydrochloride after 80% of
the patients had been treated with glucosamine sul-
phate because the manufacturer of glucosamine sul-
phate declined to supply matching placebos.36 Three
trials (1229 patients) compared chondroitin sulphate
with placebo,37 38 43 and one trial (1265 patients) com-
pared glucosamine hydrochloride, chondroitin sul-
phate, and their combination with placebo.13
Tables 1 and 2 show the characteristics of trials.
Six trials described adequate concealment of
allocation,13 35 36 39 41 43 nine trials reported adequate
blinding of patients, and in one trial34 it was unclear.
Seven trials performed an intention to treat
RESEARCH
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analysis.13 34-37 41 43 Eight trials included patients with
osteoarthritis of the knee only,13 33-37 39 43 one trial
included patients with osteoarthritis of the hip or
knee,38 and one trial included patients with osteoarthri-
tis of the hip only.41 All except three trials13 36 41 were
funded by manufacturers of supplements. In eight
trials, experimental preparations had undergone qual-
ity control to ensure adequate concentrations of gluco-
samine or chondroitin, and in two trials38 41 it was
unclear. The average age of patientswas 58-66 (median
62), and the percentage of women ranged from 27% to
86% (median 68%). The average duration of symptoms
ranged from a minimum of six months to more than
10 years. All treatments were administered on conse-
cutive days in all trials. Duration of follow-up varied
substantially between trials, from one month33 to
36months,34 35 and the number of follow-up visits from
one1333 34 37 to 1235 (table 1).
Effects on joint pain
All trials contributed to the network meta-analysis of
pain related outcomes (see appendix 1 on bmj.com).
Figure 2 presents pooled estimates across different
time points. The variation across time points was not
over and above what would be expected by chance
(τ2=0.04 for variation across time points on a 10 cm
visual analogue scale, P=0.93 for interaction between
treatment effect and time). The overall difference in
pain intensity versus placebo based on a summary of
all time points was −0.4 cm (95% credible interval −0.7
to −0.1 cm) on a 10 cm visual analogue scale for gluco-
samine, −0.3 cm (−0.7 to 0.0 cm) for chondroitin, and
−0.5 cm (−0.9 to 0.0 cm) for the combination of gluco-
samine and chondroitin. Corresponding effect sizes
were −0.17 (−0.28 to −0.05) for glucosamine, −0.13
(−0.27 to 0.00) for chondroitin, and −0.19 (−0.37 to
0.00) for the combination. Heterogeneity between
trials was low (τ2=0.04 for heterogeneity between trials
on a 10 cm visual analogue scale), there was no evi-
dence for inconsistency (inconsistency factor 0.2 cm,
−0.7 to 1.1, P=0.63), and the goodness of fit of the
model to the data was excellent (data available on
request). Results from the primary network meta-ana-
lysis were concordant with a model including a linear
term for time, conventional meta-analyses of direct
comparisons, a networkmeta-analysis, which included
only one time point for pain intensity at the end of
follow-up, and an analysis with a different prior
Table 1 | Characteristics of identified randomised trials of glucosamine or chondroitin for osteoarthritis of hip or knee
Study
Quality
controlled
preparation
Treatment
duration
(weeks)
Conceal-
ment
adequate
Patient
blinding
adequate
ITT
per-
formed
Mean
age
(years)
%
women
Symptom
duration
(years)
Joint
affected
Pain outcome
extracted Funding Source
Time point
extracted
(months)
Glucosamine v placebo
Noack 199433 Yes 1-4 Unclear Yes No NA NA ≥0.5 Knee Lequesne Rottapharm 1
Reginster 200134 Yes 1-156 Unclear Unclear Yes 66 76 7.8 Knee WOMAC pain
subscale
Rottapharm 36
Pavelka 200235 Yes 1-156 Yes Yes Yes 62 78 10.6 Knee Lequesne Rottapharm 3,6, (…),36
McAlindon
200436
Yes 1-12 Yes Yes Yes 61 64 NA Knee WOMAC pain
subscale
NLMandArthritis
Foundation
3
Herrero-
Beaumont
200739
Yes 1-26 Yes Yes No 64 86 10.4 Knee Lequesne Rottapharm 3,6
Rozendaal
200841
Unclear 1-104 Yes Yes Yes 64 69 >3* Hip Global pain ErasmusMedical
Center
Breedtestrategie
3,6, (…),24
Chondroitin v placebo
Michel 200537 Yes 1-103 Unclear Yes Yes 63 52 NA Knee WOMAC pain
subscale
IBSA 24
Mazières 200738 Unclear 1-26 Unclear Yes Unclear 61 62 NA Hip or knee Painonactivity Pierre Fabre 3,6,9
Kahan 200943 Yes 1-132 Yes Yes Yes 62 68 6.5 Knee Global pain IBSA 3,6, (…),24
Glucosamine v chondroitin v glucosamine and chondroitin combined v placebo
Clegg 200613 Yes 1-24 Yes Yes Yes 58 27 9.6 Knee WOMAC pain
subscale
NIH 6
NA=not available; NIH=US National Institute of Health; NLM=US National Library of Medicine.
*Duration >3 years for more than half of patients.
(7 trials,
1939 patients)
(4 trials,
1840 patients)
(one trial,
635 patients)
Placebo
Chondroitin Glucosamine
Chondroitin and
glucosamine
(one trial,
634 patients)
(one trial,
630 patients)
(one trial,
635 patients)
Fig 1 | Structure of network formed by interventions and their
direct comparisons. Numbers of trials and patients do not add
up to numbers reported in table 2 because of multi-arm trial
by Clegg et al13
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distribution for the heterogeneity between trials (see
appendix 2 on bmj.com).
Figure 3 shows the results from stratified analyses.
Estimates comparing supplements with placebo
depended to some extent on the quality of the trials,
the presence or absence of quality control measures
for preparations, the type of study joint, and the type
of glucosamine salt used, but tests for interaction were
all negative for these variables (P≥0.20 for interaction).
The estimated differences between supplements and
placebo, however, were, on average, 0.5 cm (0.1 to
0.9 cm) less pronounced in industry independent trials
compared with industry sponsored trials (P=0.02 for
interaction).
Effects on radiological joint space
Six trials reported changes in width of joint
space.34 35 37 41-43 The network meta-analysis of differ-
ences in changes in minimal joint space narrowing at
the end of the treatment period showed minute effects
for all preparations comparedwith placebo. The differ-
ence was −0.2 mm (−0.3 to 0.0 mm) in favour of gluco-
samine, −0.1 mm (−0.3 to 0.1 mm) in favour of
chondroitin, and 0.0mm (−0.2 to 0.2mm) for the com-
bination, which corresponded to effect sizes of −0.16
(−0.25 to 0.0), −0.08 (−0.25 to 0.08), and 0.00 (−0.16 to
0.16). Heterogeneity between trials was low (τ2=0.02),
there was no evidence for inconsistency (inconsistency
factor−0.1mm,−0.6 to 0.4mm;P=0.54), and the good-
ness of fit of the model to the data was excellent.
Safety
Five trials reported on adverse events,33-35 38 41 all 10
reported withdrawals or drop-outs because of adverse
events, and three reported serious adverse events.33 38 41
The odds ratios of adverse events compared with
placebo were 0.94 (0.59 to 1.47) for glucosamine and
0.99 (0.49 to 2.00) for chondroitin; no data were avail-
able on adverse events overall for the combination.
The odds ratios for withdrawals or drop-outs because
of adverse events were 0.99 (0.61 to 1.50) for glucosa-
mine, 0.92 (0.56 to 1.51) for chondroitin, and0.90 (0.43
to 1.85) for the combination. Heterogeneity between
trials was low for both outcomes, with τ2 of 0.02 and
0.03, respectively. We could estimate inconsistency
only for drop-outs because of adverse events, with
some evidence of inconsistency (ratio of relative risks
0.54, 0.19 to 1.46, P=0.22 for inconsistency).
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Fig 2 | Differences in pain intensity measured on visual
analogue scale (VAS) between experimental interventions and
placebo over time. Shading represents area of clinical
equivalence. Negative values indicate benefit of experimental
interventions compared with placebo
Table 2 | Characteristics of identified randomised trials of glucosamine or chondroitin for osteoarthritis of hip or knee by
treatment arm
Trial Treatment (daily dose)
Patients
randomised
Patients analysed
for pain
Patients analysed
for joint space
Glucosamine v placebo
Noack 199433 Glucosamine sulphate (1500 mg)/placebo 126/126 120/121 NA
Reginster 200134 Glucosamine sulphate (1500 mg)/placebo 106/106 106/106 106/106
Pavelka 200235 Glucosamine sulphate (1500 mg)/placebo 101/101 101/101 101/101
McAlindon 200436 Glucosamine sulphate (1500 mg) or glucosamine
hydrochloride (1500 mg)/placebo
101/104 101/104 NA
Herrero-Beaumont
200739
Glucosamine (1500 mg)/placebo 109/107 106/104 NA
Rozendaal 200841 Glucosamine (1500 mg)/placebo 111/111 111/111 111/111
Chondroitin v placebo
Michel 200537 Chondroitin sulphate (800 mg)/placebo 150/150 150/150 150/150
Mazières 200738 Chondroitin sulphate (1000 mg)/placebo NA 153/154 NA
Kahan 200943 Chondroitin sulphate (800 mg)/placebo 309/313 309/313 309/313
Glucosamine v chondroitin v glucosamine and chondroitin combined v placebo
Clegg 200613 Glucosamine hydrochloride (1500 mg)/
chondroitin sulphate (1200 mg)/glucosamine
hydrochloride (1500mg) and chondroitin sulphate
(1200 mg)/placebo
317/318/317/313 317/318/317/313 77/71/59/70
NA=not available.
RESEARCH
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DISCUSSION
Principal findings
Our network meta-analysis of all 10 available large
scale patient blind randomised trials in 3803 patients
with knee or hip osteoarthritis showed no clinically
relevant effect of chondroitin, glucosamine, or their
combinationonperceived joint pain.Despite abundant
statistical power, none of the pooled estimates crossed
the pre-specified boundary of a minimal clinically
important difference of −0.9 cm on a 10 cm visual ana-
logue scale at any of the recorded time points. At some
time points the 95% credible interval crossed this
boundary (see fig 3), which could mean that we cannot
exclude a relevant effect at such time points. The over-
all estimates, which combine effects over different time
points, were precise, however, and the lower end of
their credible intervals did not cross the pre-specified
boundary. These estimates should be considered most
valid in view of the negative test of interaction of treat-
ment effects by time (P=0.93), which indicates that the
observedvariationoverdifferent timepoints is not over
and above what would be expected by chance alone.
The upper limit of the 95% credible interval of the
overall pooled estimate of glucosamine versus placebo
and chondroitin versus placebo did not overlap the
line of no effect, which suggests that a traditional
P value for this comparison would be significant at
the conventional 5% level. Statistical significance
should not, however, be confused with clinical rele-
vance. With the observed differences in pain intensity
of 0.3 to 0.5 cmbetween supplements and placebo on a
10 cm visual analogue scale, the range and distribution
of pain scores in patients receiving supplements and
placebo are near identical,9 23 and it would be impossi-
ble, based on the reported pain intensity at the end of a
trial, to determine whether a patient was allocated to a
supplement or to placebo.
In stratified analyses, we found that estimates com-
paring supplements with placebo depended to some
extent on the quality of the trials, the presence or
absence of quality control measures for preparations,
the joint studied, and the type of glucosamine salt
used, but tests for interaction were all negative for
these variables (P≥0.20 for interaction). On average,
the estimated differences between supplements and pla-
cebo were 0.5 cm less pronounced in industry indepen-
dent trials comparedwith industry sponsored trials, and
estimated treatment effects in industry independent
trials were minute to zero and by no means clinically
relevant (see fig 2). The effects on minimal width of
All trials
Concealment of allocation
  Adequate
  Unclear
Blinding of patients
  Adequate
  Unclear
Intention to treat analysis
  Yes
  No or unclear
High quality trials
  Yes
  No
Quality control of preparations
  Yes
  No
Funding independent of industry
  Yes
  No
Joints studied
  Exclusively knees
  Hips or knees
Types of glucosamine
  Glucosamine sulphate
  Glucosamine hydrochloride
-0.4 (-0.7 to -0.1)
-0.4 (-0.7 to -0.1)
-0.5 (-1.0 to 0.0)
-0.4 (-0.7 to -0.1)
-0.2 (-1.2 to 0.8)
-0.4 (-0.6 to 0.0)
-0.7 (-1.1 to -0.1)
-0.4 (-0.7 to 0.0)
-0.6 (-1.0 to -0.1)
-0.5 (-0.8 to -0.1)
-0.3 (-0.9 to 0.2)
-0.1 (-0.5 to 0.2)
-0.6 (-0.9 to -0.3)
-0.5 (-0.8 to -0.1)
-0.3 (-0.9 to 0.2)
-0.5 (-0.7 to -0.2)
-0.1 (-0.8 to 0.7)
-2 -1 0 1
Combination
superior
Placebo
superior
Difference in means
on 10 cm VAS
-2 -1 0 1
Chondroitin
superior
Placebo
superior
Difference in means
on 10 cm VAS
-2-3 -1 0 1 2 -3 2 -3 2
Glucosamine
superior
Placebo
superior
Difference in means
on 10 cm VAS
Glucosamine v placebo
-0.3 (-0.7 to 0.0)
-0.3 (-0.7 to 0.1)
-0.4 (-0.9 to 0.1)
-0.3 (-0.7 to 0.0)
-0.1 (-1.2 to 1.0)
-0.2 (-0.6 to 0.1)
-0.5 (-1.1 to 0.0)
-0.2 (-0.6 to 0.1)
-0.5 (-1.1 to 0.0)
-0.4 (-0.7 to 0.0)
-0.2 (-0.8 to -0.1)
0.1 (-0.3 to 0.6)
-0.4 (-0.7 to -0.1)
-0.4 (-0.7 to 0.0)
-0.2 (-0.8 to 0.3)
-0.4 (-0.7 to 0.0)
0.0 (-0.7 to 0.8)
Chondroitin v placebo
-0.5 (-0.9 to 0.0)
-0.4 (-0.9 to 0.0)
-0.5 (-0.9 to 0.0)
-0.4 (-0.9 to 0.0)
-0.4 (-0.9 to 0.0)
-0.5 (-0.9 to 0.0)
-0.3 (-0.7 to 0.2)
-0.5 (-0.9 to 0.0)
-0.3 (-0.8 to 0.2)
Combination v placebo
0.62
0.62
0.24
0.31
0.62
0.02
0.62
0.28
P for
interaction
Fig 3 | Stratified analyses of differences (95% confidence interval) on 10 cm visual analogue scale (VAS) in pain intensity between experimental interventions
and placebo. Shading represents area of clinical equivalence. Negative values indicate benefit of experimental interventions compared with placebo
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joint space were small, again clinically irrelevant, and—
with credible intervals overlapping the line of no effect
—non-significant at the conventional α level of 5%.
Strengths and weaknesses
Our network meta-analysis integrated evidence from
direct and indirect comparisons while fully preserving
randomisation. It enabled us to simultaneously analyse
effect sizes reported at different follow-up times in a
single model and to estimate the overall effect of pre-
parations irrespective of the duration of follow-up
while fully accounting for potential variation across
time points and for the correlation of estimates within
a trial. Consequently, estimates in our analysis were
more precise than the pairwise meta-analyses or the
network meta-analysis with only pain intensity at the
end of follow-up (see appendix 2 on bmj.com).
Weperformed an extensive literature search,44 which
makes it unlikely that wemissed any relevant trial. Trial
selection and data extraction including quality assess-
ment were done independently by two authors tomini-
mise bias and transcription errors.45 Components used
for quality assessment are validated and reported to be
associated with bias.121946 In line with our pre-specified
inclusion criteria, the trials in our network were large
and of satisfactory methodological quality.
As with conventional meta-analyses, some will argue
that we have not compared like with like. Our model,
however, was based on relative treatment effects (differ-
ences between groups expressed as effect sizes23), and
variations in patients’ characteristics between trials are
fully accounted for in the analysis bymaintaining rando-
misedcomparisonswithin each trial.Networkmeta-ana-
lysis makes similar assumptions to standard meta-
analysis of direct comparisons within trials but requires
that these assumptions hold over the entire set of trials in
the network—that is, for the indirect comparisons also.
In addition, our model assumes that relative treatment
effects comparing two interventions in different trials are
from the same common distribution. The smaller the
heterogeneity between trials, and the smaller the incon-
sistency between direct randomised comparisons and
indirect comparisons, themore likely these assumptions
hold. The heterogeneity between trials in our analysis
was near zero and the upper credible interval for the τ2
estimate was 0.24 on a 10 cm visual analogue scale (the
maximum τ of the underlying distribution of treatment
effects compatible with the credible interval would be
0.5 cm). In addition, we investigated potential sources
of variation in the network by including characteristics
of trials as covariates in the analysis of the primary out-
come. Taken together, results of these analyses make it
likely that relative treatment effects originate from one
common distribution and confirm one of our key
assumptions. As with heterogeneity between trials,
inconsistency between direct and indirect comparisons
was also near zero (inconsistency factor 0.2 cm).
Althoughwe cannot rule out clinically relevant inconsis-
tency (the upper credible interval for the inconsistency
factor crossed the pre-specified threshold for a clinically
relevant effect at 0.9 cm), we have no indication that
clinical characteristics of included patients or other trial
characteristics confounded the indirect comparisons.
The use of different instruments to measure joint pain
made it necessary to calculate effect sizes as a common
measure of effectiveness to ensure comparability
between outcomes assessed with different instruments.
Poor correlation or differences in responsiveness of dif-
ferent instruments could be a potential threat to the
validity of results.47 The scales used in the component
trials of our network (10 cm visual analogue scale and
WOMAC pain subscales), however, were highly corre-
lated and have comparable responsiveness.48
Relation to other studies
Several systematic reviews andmeta-analysesongluco-
samine and chondroitin have been published.8101149-52
The three most recent ones were by Vlad et al11 on
glucosamine, Reichenbach et al10 on chondroitin, and
Lee et al52 on radiographic outcomes of both prepara-
tions.Vlad andcolleagues analysed 15 trials comparing
glucosamine with placebo.11 They found a pooled
effect size of −0.35 (95% confidence interval −0.56 to
−0.14) in favour of glucosamine, but there was substan-
tial heterogeneity. Trials with adequate concealment of
allocation, industry independent trials, and trials eval-
uating glucosamine hydrochloride showed less benefi-
cial effects and less pronounced heterogeneity between
trials than the remainder. The authors concluded that
glucosamine hydrochloride is ineffective but could not
exclude the possibility of a clinically relevant effect of
glucosamine sulphate. Reichenbach and colleagues
found large heterogeneity among 20 chondroitin trials,
which could be explained by a lack of concealment of
allocation, failure to perform an intention to treat ana-
lysis, and small sample sizes.10 The initial pooled effect
size of −0.75 (−0.99 to −0.50) in favour of chondroitin
sulphate diminished to zero when the analysis was
restricted to methodologically sound trials of adequate
sample size. Both groups had analysed only one time
point per trial, which was criticised.40 Lee and collea-
gues included six trials evaluating the effects of chon-
droitin or glucosamine on narrowing of joint space
(four were included in our analysis and we excluded
two because of small sample size).52 They found signifi-
cant small tomoderate protective effects. They did not,
however, include the GAIT trial.42 We included meth-
odologically superior large scale patient blinded trials
inmore than 200 patients in our networkmeta-analysis
and used a statistical model that allowed the simulta-
neous analysis and summary of treatment effects
observed at multiple time points. Addressing earlier
concerns about time dependency of effects,40 quality
control of preparations,53 and differences between dif-
ferent formulations of glucosamine,11 we conclude that
there is no evidence for time dependent effects, that the
lack of a clinically relevant effect of these preparations
is not related to a lack of quality control, and that the
lack of a clinically relevant effect is also apparent for
glucosamine sulphate. With the summary of multiple
time points and the combination of direct comparisons
within trials between preparations with indirect
RESEARCH
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evidence from other trials, these conclusions are based
on considerably more high quality evidence than the
previous restricted analyses of trials considered least
biased by Vlad et al and Reichenbach et al.10 11
Implications
We believe it unlikely that future trials will show a clini-
cally relevant benefit of any of the evaluated prepara-
tions. Some will argue, however, that many patients
included in the trials of our networkwere too ill in radio-
logical terms to benefit and that their advanced radio-
logical stage meant that the subtotal to total cartilage
damage couldnot be influenced anymore by the experi-
mental preparations. Others will argue that many
patients were not ill enough in clinical terms and that
their small amount of experienced pain meant that
they could not benefit from the analgesic effects of the
preparations.54 To address these concerns, in addition to
the trials byClegg et al,13 Rozendaal et al,41 andMcAlin-
donet al,36 somemight consider thenecessity fora fourth
industry independent trial, which would exclusively
include patients with an experienced pain intensity at
baseline of at least 4 cm on a 10 cm visual analogue
scale and moderate osteoarthritis, corresponding to a
Kellgren and Lawrence score of 2.55 Inclusion of 150 to
200 patients in each comparison group would yield
more than 90%power todetect aminimal clinically rele-
vant difference of −0.9 cm on a 10 cm visual analogue
scale for any of these preparations compared with pla-
cebo at a conventional two sided α level of 5%. The trial
should use coded drug packs with preparations and pla-
cebos of identical appearance and taste to conceal treat-
ment allocation and ensure blinding of patients and care
givers, carefully control and monitor analgesic cointer-
ventions, and fully adhere to the principle of intention to
treat by the inclusion of all patients in the analysis in the
groups towhich theywereoriginally allocated.The eval-
uated preparations should have undergone thorough
quality control to ensure appropriate concentrations of
chondroitin and glucosamine sulphate. The industry
independent randomised Long Term Evaluation of
Glucosamine Sulphate Study (LEGS) will probably
satisfy most of these criteria.56 It allocated 600 patients
to one of four treatment arms— chondroitin sulphate,
glucosamine sulphate, their combination, or matching
placebo—and closed recruitment in October 2009.
First results will become available at the earliest in
November 2011 (MFransen, personal communication).
Conclusions
Our findings indicate that glucosamine, chondroitin,
and their combination donot result in a relevant reduc-
tion of joint pain nor affect joint space narrowing com-
pared with placebo. Some patients, however, are
convinced that these preparations are beneficial,57
which might be because of the natural course of
osteoarthritis, regression to the mean, or the placebo
effect.58 We are confident that neither of the prepara-
tions is dangerous. Therefore, we see no harm in hav-
ing patients continue these preparations as long as they
perceive a benefit and cover the costs of treatment
themselves.57 Coverage of costs by health authorities
or health insurers for these preparations and novel pre-
scriptions to patients who have not received other
treatments should be discouraged.
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